Interstitial Pneumonitis-A Newly Recognized Consequence of Intravesical Gemcitabine Therapy

Am J Ther. 2022 Nov-Dec;29(6):e752-e754. doi: 10.1097/MJT.0000000000001206. Epub 2020 Jun 2.

Authors

Venkata Satish Pendela¹, Bassil Said¹, Pujitha Kudaravalli², Mamta Chhabria¹, Dharmini Manogna¹, Michael Gurell³

Affiliations

¹ Department of Internal Medicine, Rochester General Hospital, Rochester, NY.
² Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY.
³ Department of Pulmonary Medicine, Rochester General Hospital, Rochester, NY.

PMID: 32516143
DOI: 10.1097/MJT.0000000000001206

No abstract available

Publication types

Letter

MeSH terms

Antimetabolites, Antineoplastic / adverse effects
Gemcitabine
Humans
Lung Diseases, Interstitial* / chemically induced
Lung Diseases, Interstitial* / diagnosis
Lung Diseases, Interstitial* / drug therapy
Urinary Bladder Neoplasms* / drug therapy

Substances

Gemcitabine
Antimetabolites, Antineoplastic